Patents by Inventor Maarten Penning
Maarten Penning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230370733Abstract: A sensor arrangement includes a first, second, third and fourth group of receiving elements for detecting light in the red, green, blue and infrared wavelength range. At least one first sub-arrangement is formed by arranging one receiving element of the first group, two receiving elements of the second group and one receiving element of the third group in a first Bayer-like pattern. At least one second sub-arrangement is formed by arranging two receiving elements of the second group one receiving element of the fourth group and one receiving element of the first or the third group in a second Bayer-like pattern. The at least one first sub-arrangement and the at least one second sub-arrangement are arranged adjacent to each other in a main plane of extension of the sensor arrangement.Type: ApplicationFiled: September 14, 2021Publication date: November 16, 2023Applicant: ams Sensors Belgium BVBAInventors: Maarten PENNINGS, Johan DE MEULDER
-
Publication number: 20220064740Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: September 15, 2021Publication date: March 3, 2022Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 11149317Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: October 8, 2018Date of Patent: October 19, 2021Assignee: Exact Sciences Development Company, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 10808286Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: May 4, 2018Date of Patent: October 20, 2020Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20190032149Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: October 8, 2018Publication date: January 31, 2019Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20180327859Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: May 4, 2018Publication date: November 15, 2018Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 9982308Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: February 4, 2015Date of Patent: May 29, 2018Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20150240318Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging, or otherwise characterizing various diseases.Type: ApplicationFiled: February 4, 2015Publication date: August 27, 2015Applicant: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Patent number: 8969046Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: January 9, 2008Date of Patent: March 3, 2015Assignee: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Patent number: 8608960Abstract: Provided are methods of separating an immunoreactive compound from at least one immaterial component, using a simulated moving bed (“SMB”) system and a SMB apparatus for use in these methods. Also provided are purified immunoreactive compounds prepared using the SMB methods and apparatus and methods of treatment with the purified immunoreactive compounds.Type: GrantFiled: May 21, 2007Date of Patent: December 17, 2013Assignee: Biogen Idec Inc.Inventors: Jorg Thommes, Alan M. Sonnenfeld, John P. Pieracci, Lynn Conley, Marc Bisschops, Maarten Pennings
-
Publication number: 20100144836Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, 11112, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: January 9, 2008Publication date: June 10, 2010Applicant: ONCOMETHYLOME SCIENCES SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20070215534Abstract: Provided are methods of separating an immunoreactive compound from at least one immaterial component, using a simulated moving bed (“SMB”) system and a SMB apparatus for use in these methods. Also provided are purified immunoreactive compounds prepared using the SMB methods and apparatus and methods of treatment with the purified immunoreactive compounds.Type: ApplicationFiled: May 21, 2007Publication date: September 20, 2007Inventors: Jorg Thommes, Alan Sonnenfeld, John Pieracci, Lynn Conley, Marc Bisschops, Maarten Pennings
-
Publication number: 20070143277Abstract: The present invention provides a system and method for storing a single file comprising multiple parts of content data and for selectively downloading at least one part thereof, including: the relevant files out of a zip-archive instead of the whole archive; a chapter instead of the whole book; the cover image out of an MP3 file; and the thumbnail of a jpg with exif header. The storing of various parts of data about an entity in a single file also provides the advantage of avoiding inconsistencies between the various parts. Often data and meta-data are combined in one file (this is already done to avoid inconsistencies between the parts). Examples in which this is currently done include: in one file have the whole image and its thumbnail; MP3 files already can contain an image of the CD cover together with the music; JPG files (with exif header) can contain meta-data (e.g. flash used, exposure) about the photograph.Type: ApplicationFiled: November 11, 2004Publication date: June 21, 2007Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Pierre Van De Laar, Christiaan Aarts, Maarten Pennings
-
Publication number: 20070077578Abstract: The invention provides a method for typing a sample of an individual suffering from, or at risk of suffering from, a disease and a method for monitoring treatment of an individual suffering from a disease comprising determining whether a sample from the individual comprises an expression product of AC133 in an amount that is indicative for the disease or for the treatment thereof. That amount is preferably quantified and compared with a reference value. In one aspect, the amount is compared with an amount of the expression product present in a sample that was obtained from the individual before treatment. Use of a nucleic acid molecule comprising at least part of a sequence of AC133, or an analogue thereof, for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid molecule.Type: ApplicationFiled: August 31, 2006Publication date: April 5, 2007Applicants: PrimaGen Holding B.V., UMC Utrecht Holding B.V.Inventors: Maarten Penning, Sebastiaan van den Broek, Emile Voest, Laurens Beerepoot, Niven Mehra
-
Publication number: 20040241878Abstract: Provided are methods of separating an immunoreactive compound from at least one immaterial component, using a simulated moving bed (“SMB”) system and a SMB apparatus for use in these methods. Also provided are purified immunoreactive compounds prepared using the SMB methods and apparatus and methods of treatment with the purified immunoreactive compounds.Type: ApplicationFiled: September 12, 2003Publication date: December 2, 2004Inventors: Jorg Thommes, Alan M. Sonnenfeld, John P. Pieracci, Lynn Conley, Marc Bisschops, Maarten Pennings